Email Updates

You are here

AVAC's Blog: P-Values

  • We are only a month into the New Year and so much has happened in HIV prevention. Below are links to important resources on the latest developments. Opinion Piece: The Fight to Decriminalize Sex Work in South Africa: South Africa-based AVAC Fellow, Liyema Somnono published an opinion piece in Health-e News, Decriminalization of sex work can help prevent HIV, which unpacks the reasons for reforming South Africa’s outdated legislation that criminalizes “sex work” and legitimizing and recognizing sex work as work.

    February 2, 2023
    General
  • South Africa could possibly reform its outdated and misguided criminal legislation that punishes consenting adults who offer or procure sexual services for money. AVAC supports the move toward decriminalization as evidence shows that its social, legal and economic injustices create a perfect storm for sex workers’ increased HIV risk.

    January 27, 2023
    General
    Cindra Feuer
  • AVAC has two webinars this week you won’t want to miss! Tomorrow, January 25, at 9 AM PST/12 PM EST/6 PM CET, AVAC and HIV Vaccine Trials Network (HVTN) will host a webinar called Where Are We and Next Steps. As the field explores what the ending of the Mosaico study means for vaccine research, we’ll be joined by study investigators and community representatives to further interrogate what a post Mosaico trial looks like, key takeaways from the study, and ways to remain hopeful for an HIV vaccine. Register here.

    January 24, 2023
  • On the heels of Wednesday’s announcement from Janssen Pharmaceutical Company that the Mosaico HIV vaccine trial is ending for lack of efficacy, there’s much to learn and discuss. Please join AVAC and the HIV Vaccine Trials Network (HVTN) for a webinar on January 25th at 9am PST/12pm EST/6pm CET. The webinar will include study investigators and community representatives as we all discuss the outcome of the Mosaico study, what these results mean and next steps. Register here.

    January 20, 2023
    AVAC
  • The Mosaico study, a large-scale HIV vaccine efficacy study also known as HVTN 706/HPX3002, was stopped early for non-efficacy. An independent data and safety monitoring board, at a scheduled review of the trial data, found the regimen to be safe, but that it did not meet the pre-defined criteria for efficacy and recommended that the study be stopped and trial participants informed.

    January 18, 2023
  • AVAC is excited to launch the Advocacy Navigator, an extension of our Advocacy Fellows program, which has involved more than 90 advocates and dozens of civil society organizations in 15 countries to drive groundbreaking advocacy on HIV prevention research, rollout, and human rights. AVAC now seeks applications from early-career professionals from Eastern and Southern Africa interested in strengthening their skills in HIV prevention advocacy.

    January 17, 2023
  • At AVAC we saw tremendous work to accelerate HIV prevention and invest in global health resilience in 2022, and the year ahead will require critical advocacy to keep the field on track. What does this mean? Our year-end letter, HIV Prevention and Equity in 2022 & Beyond, explores in depth the many initiatives, resources and collaborations that powered advocacy in 2022 — a historic juncture for HIV and global health.

    January 11, 2023
    General
    AVAC
  • This year was an incredible one of reflection, engagement, opportunity, and action. More than 40 years into the HIV epidemic – and in the midst of multiple other pandemics and persistent inequities – AVAC and its partners continue to reshape, reimagine and fight for effective HIV prevention.

    December 21, 2022
    General
  • World AIDS Day is a day to remember and reflect, but it can also be a day to intensify advocacy, which was the case for many of our 2022 AVAC Advocacy Fellows. From broadcast interviews, to an open forum on religion and sexuality, to a symposium attended by the Prime Minister of Lesotho, AVAC Fellows took World AIDS Day to task with a day of conversation and advocacy. Check out highlights from the day below.

    December 15, 2022
    AVAC
  • The Choice Agenda (TCA), a global forum for advocacy on HIV prevention, is just a few new sign ups away from the 1,000 member mark!!! It’s a milestone reminding us of what the TCA has achieved in such a short time, with agenda-setting conversations and deep-dive webinars on key issues in the field and a full program to come in 2023.

    December 12, 2022
    General

Pages